Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

Destabilization of FoxM1 and Inhibition of Topoisomerase I Contribute to Cytotoxicity of Prenylated Xanthones Isolated from Metaxya rostrata.

Mittermair E, Schueffl H, Heffeter P, Krenn L, Marian B.

Planta Med. 2020 Feb 5. doi: 10.1055/a-1097-8722. [Epub ahead of print]

PMID:
32023632
2.

Importance of Translational Research for Targeting Fibroblast Growth Factor Receptor Signaling in Cancer.

Holzmann K, Marian B.

Cells. 2019 Oct 2;8(10). pii: E1191. doi: 10.3390/cells8101191.

3.

Correction: Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer.

Ahmed MA, Selzer E, Dörr W, Jomrich G, Harpain F, Silberhumer GR, Müllauer L, Holzmann K, Grasl-Kraupp B, Grusch M, Berger W, Marian B.

Oncotarget. 2019 Sep 3;10(51):5385-5386. doi: 10.18632/oncotarget.27186. eCollection 2019 Sep 3.

4.

Impact of Fibroblast-Derived SPARC on Invasiveness of Colorectal Cancer Cells.

Drev D, Harpain F, Beer A, Stift A, Gruber ES, Klimpfinger M, Thalhammer S, Reti A, Kenner L, Bergmann M, Marian B.

Cancers (Basel). 2019 Sep 24;11(10). pii: E1421. doi: 10.3390/cancers11101421.

5.

Expression of FGF8, FGF18, and FGFR4 in Gastroesophageal Adenocarcinomas.

Jomrich G, Hudec X, Harpain F, Winkler D, Timelthaler G, Mohr T, Marian B, Schoppmann SF.

Cells. 2019 Sep 16;8(9). pii: E1092. doi: 10.3390/cells8091092.

6.

Prenylated xanthones from Metaxya rostrata suppress FoxM1 and induce active cell death by distinct mechanisms.

Mittermair E, Krenn L, Marian B.

Phytomedicine. 2019 Jul;60:152912. doi: 10.1016/j.phymed.2019.152912. Epub 2019 Apr 2.

PMID:
30979690
7.

Position-Selective Synthesis and Biological Evaluation of Four Isomeric A-Ring Amino Derivatives of the Alkaloid Luotonin A.

Ibric A, Eckerstorfer S, Eder M, Louko I, Tunjic L, Heffeter P, Schueffl HH, Marian B, Haider N.

Molecules. 2019 Feb 16;24(4). pii: E716. doi: 10.3390/molecules24040716.

8.

FGF8 induces therapy resistance in neoadjuvantly radiated rectal cancer.

Harpain F, Ahmed MA, Hudec X, Timelthaler G, Jomrich G, Müllauer L, Selzer E, Dörr W, Bergmann M, Holzmann K, Grasl-Kraupp B, Grusch M, Berger W, Marian B, Silberhumer GR.

J Cancer Res Clin Oncol. 2019 Jan;145(1):77-86. doi: 10.1007/s00432-018-2757-7. Epub 2018 Oct 1.

9.

Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives.

Valent P, Hadzijusufovic E, Grunt T, Karlic H, Peter B, Herrmann H, Eisenwort G, Hoermann G, Schulenburg A, Willmann M, Hubmann R, Shehata M, Selzer E, Gleixner KV, Rülicke T, Sperr WR, Marian B, Pfeilstöcker M, Pehamberger H, Keil F, Jäger U, Zielinski C.

Wien Klin Wochenschr. 2018 Sep;130(17-18):517-529. doi: 10.1007/s00508-018-1355-7. Epub 2018 Jul 13. Review.

10.

FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal.

Schelch K, Wagner C, Hager S, Pirker C, Siess K, Lang E, Lin R, Kirschner MB, Mohr T, Brcic L, Marian B, Holzmann K, Grasl-Kraupp B, Krupitza G, Laszlo V, Klikovits T, Dome B, Hegedus B, Garay T, Reid G, van Zandwijk N, Klepetko W, Berger W, Grusch M, Hoda MA.

Carcinogenesis. 2018 Apr 5;39(4):534-545. doi: 10.1093/carcin/bgy018.

PMID:
29635378
11.

Survival and functional and oncological outcomes following intersphincteric resection for low rectal cancer: short-term results.

Molnar C, Vlad-Olimpiu B, Marian B, Cornelia T, Simona G.

J Int Med Res. 2018 Apr;46(4):1617-1625. doi: 10.1177/0300060518758841. Epub 2018 Mar 1.

12.

Proteomic profiling identifies markers for inflammation-related tumor-fibroblast interaction.

Drev D, Bileck A, Erdem ZN, Mohr T, Timelthaler G, Beer A, Gerner C, Marian B.

Clin Proteomics. 2017 Oct 6;14:33. doi: 10.1186/s12014-017-9168-7. eCollection 2017.

13.

FGF5 is expressed in melanoma and enhances malignancy in vitro and in vivo.

Ghassemi S, Vejdovszky K, Sahin E, Ratzinger L, Schelch K, Mohr T, Peter-Vörösmarty B, Brankovic J, Lackner A, Leopoldi A, Meindl D, Pirker C, Hegedus B, Marian B, Holzmann K, Grasl-Kraupp B, Heffeter P, Berger W, Grusch M.

Oncotarget. 2017 Sep 23;8(50):87750-87762. doi: 10.18632/oncotarget.21184. eCollection 2017 Oct 20.

14.

A Facile Oxidative Opening of the C-Ring in Luotonin A and Derivatives.

Ibric A, Dutter K, Marian B, Haider N.

Molecules. 2017 Sep 12;22(9). pii: E1540. doi: 10.3390/molecules22091540.

15.

Irinotecan Upregulates Fibroblast Growth Factor Receptor 3 Expression in Colorectal Cancer Cells, Which Mitigates Irinotecan-Induced Apoptosis.

Erdem ZN, Schwarz S, Drev D, Heinzle C, Reti A, Heffeter P, Hudec X, Holzmann K, Grasl-Kraupp B, Berger W, Grusch M, Marian B.

Transl Oncol. 2017 Jun;10(3):332-339. doi: 10.1016/j.tranon.2017.02.004. Epub 2017 Mar 22.

16.

Programmed death-ligand 1 expression in rectal cancer.

Jomrich G, Silberhumer GR, Marian B, Beer A, Müllauer L.

Eur Surg. 2016;48(6):352-356. doi: 10.1007/s10353-016-0447-8. Epub 2016 Oct 7.

17.

Colon cancer cell-derived 12(S)-HETE induces the retraction of cancer-associated fibroblast via MLC2, RHO/ROCK and Ca2+ signalling.

Stadler S, Nguyen CH, Schachner H, Milovanovic D, Holzner S, Brenner S, Eichsteininger J, Stadler M, Senfter D, Krenn L, Schmidt WM, Huttary N, Krieger S, Koperek O, Bago-Horvath Z, Brendel KA, Marian B, de Wever O, Mader RM, Giessrigl B, Jäger W, Dolznig H, Krupitza G.

Cell Mol Life Sci. 2017 May;74(10):1907-1921. doi: 10.1007/s00018-016-2441-5. Epub 2016 Dec 24.

18.

Integration into plant biology and soil science has provided insights into the total environment.

Shao H, Lu H, Xu G, Marian B.

Sci Total Environ. 2017 Feb 1;579:928-929. doi: 10.1016/j.scitotenv.2016.10.167. Epub 2016 Nov 11.

PMID:
27839762
19.

Romania - UEMS, EBO.

Marian B, Cornel S.

Rom J Ophthalmol. 2016 Oct-Dec;60(4):207-208. No abstract available.

20.

Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer.

Ahmed MA, Selzer E, Dörr W, Jomrich G, Harpain F, Silberhumer GR, Müllauer L, Holzmann K, Grasl-Kraupp B, Grusch M, Berger W, Marian B.

Oncotarget. 2016 Oct 25;7(43):69976-69990. doi: 10.18632/oncotarget.12099. Erratum in: Oncotarget. 2019 Sep 03;10(51):5385-5386.

21.

Epithelial splicing regulatory protein 1 and 2 paralogues correlate with splice signatures and favorable outcome in human colorectal cancer.

Deloria AJ, Höflmayer D, Kienzl P, Łopatecka J, Sampl S, Klimpfinger M, Braunschmid T, Bastian F, Lu L, Marian B, Stättner S, Holzmann K.

Oncotarget. 2016 Nov 8;7(45):73800-73816. doi: 10.18632/oncotarget.12070.

22.

Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression.

Englinger B, Lötsch D, Pirker C, Mohr T, van Schoonhoven S, Boidol B, Lardeau CH, Spitzwieser M, Szabó P, Heffeter P, Lang I, Cichna-Markl M, Grasl-Kraupp B, Marian B, Grusch M, Kubicek S, Szakács G, Berger W.

Oncotarget. 2016 Aug 2;7(31):50161-50179. doi: 10.18632/oncotarget.10324.

23.

Fibroblast growth factor receptor 3 isoforms: Novel therapeutic targets for hepatocellular carcinoma?

Paur J, Nika L, Maier C, Moscu-Gregor A, Kostka J, Huber D, Mohr T, Heffeter P, Schrottmaier WC, Kappel S, Kandioler D, Holzmann K, Marian B, Berger W, Grusch M, Grasl-Kraupp B.

Hepatology. 2015 Dec;62(6):1767-78. doi: 10.1002/hep.28023. Epub 2015 Oct 16.

PMID:
26235436
24.

IL10R2 Overexpression Promotes IL22/STAT3 Signaling in Colorectal Carcinogenesis.

Khare V, Paul G, Movadat O, Frick A, Jambrich M, Krnjic A, Marian B, Wrba F, Gasche C.

Cancer Immunol Res. 2015 Nov;3(11):1227-35. doi: 10.1158/2326-6066.CIR-15-0031. Epub 2015 Jun 30.

25.

Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?

Schulenburg A, Blatt K, Cerny-Reiterer S, Sadovnik I, Herrmann H, Marian B, Grunt TW, Zielinski CC, Valent P.

J Hematol Oncol. 2015 Feb 25;8:16. doi: 10.1186/s13045-015-0113-9. Review.

26.

Effect of 1,25-dihydroxyvitamin D3 on the Wnt pathway in non-malignant colonic cells.

Gröschel C, Aggarwal A, Tennakoon S, Höbaus J, Prinz-Wohlgenannt M, Marian B, Heffeter P, Berger W, Kállay E.

J Steroid Biochem Mol Biol. 2016 Jan;155(Pt B):224-30. doi: 10.1016/j.jsbmb.2015.02.011. Epub 2015 Mar 14.

PMID:
25777538
27.

Autonomous inhibition of apoptosis correlates with responsiveness of colon carcinoma cell lines to ciglitazone.

Baron DM, Kaindl U, Haudek-Prinz VJ, Bayer E, Röhrl C, Gerner C, Marian B.

PLoS One. 2014 Dec 11;9(12):e114158. doi: 10.1371/journal.pone.0114158. eCollection 2014.

28.

Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy.

Schelch K, Hoda MA, Klikovits T, Münzker J, Ghanim B, Wagner C, Garay T, Laszlo V, Setinek U, Dome B, Filipits M, Pirker C, Heffeter P, Selzer E, Tovari J, Torok S, Kenessey I, Holzmann K, Grasl-Kraupp B, Marian B, Klepetko W, Berger W, Hegedus B, Grusch M.

Am J Respir Crit Care Med. 2014 Oct 1;190(7):763-72. doi: 10.1164/rccm.201404-0658OC.

PMID:
25188816
29.

Fibroblast growth factor receptor 4: a putative key driver for the aggressive phenotype of hepatocellular carcinoma.

Gauglhofer C, Paur J, Schrottmaier WC, Wingelhofer B, Huber D, Naegelen I, Pirker C, Mohr T, Heinzle C, Holzmann K, Marian B, Schulte-Hermann R, Berger W, Krupitza G, Grusch M, Grasl-Kraupp B.

Carcinogenesis. 2014 Oct;35(10):2331-8. doi: 10.1093/carcin/bgu151. Epub 2014 Jul 16.

PMID:
25031272
30.

Canine and human sarcomas exhibit predominant FGFR1 expression and impaired viability after inhibition of signaling.

Schweiger N, Hauck M, Steinhoff H, Sampl S, Reifinger M, Walter I, Kreilmeier T, Marian B, Grusch M, Berger W, Holzmann K, Kleiter M.

Mol Carcinog. 2015 Sep;54(9):841-52. doi: 10.1002/mc.22155. Epub 2014 Apr 9.

PMID:
24719266
31.

Autocrine fibroblast growth factor 18 signaling mediates Wnt-dependent stimulation of CD44-positive human colorectal adenoma cells.

Koneczny I, Schulenburg A, Hudec X, Knöfler M, Holzmann K, Piazza G, Reynolds R, Valent P, Marian B.

Mol Carcinog. 2015 Sep;54(9):789-799. doi: 10.1002/mc.22146. Epub 2014 Mar 12.

32.

Modulation of Wnt Activity and Cell Physiology by Butyrate in LT97 Microadenoma Cells.

Lazarova D, Lee A, Wong T, Marian B, Chiaro C, Rainey C, Bordonaro M.

J Cancer. 2014 Feb 14;5(3):203-13. doi: 10.7150/jca.8569. eCollection 2014.

33.

Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?

Heinzle C, Erdem Z, Paur J, Grasl-Kraupp B, Holzmann K, Grusch M, Berger W, Marian B.

Curr Pharm Des. 2014;20(17):2881-98. Review.

34.

2-deprenyl-rheediaxanthone B isolated from Metaxya rostrata induces active cell death in colorectal tumor cells.

Kainz KP, Krenn L, Erdem Z, Kaehlig H, Zehl M, Bursch W, Berger W, Marian B.

PLoS One. 2013 Jun 11;8(6):e65745. doi: 10.1371/journal.pone.0065745. Print 2013. Erratum in: PLoS One. 2013;8(9). doi:10.1371/annotation/f4e4a7b2-f60d-4102-a56f-37666aafd7e1.

35.

Two Unusual Methylidenecyclopropane Glucosides from Metaxya rostrata C.Presl.

Kainz KP, Virtbauer J, Kählig H, Arion V, Donath O, Reznicek G, Huber W, Marian B, Krenn L.

Helv Chim Acta. 2012 Sep;95(9):1531-1537. Epub 2012 Sep 13.

36.

Differential effects of polymorphic alleles of FGF receptor 4 on colon cancer growth and metastasis.

Heinzle C, Gsur A, Hunjadi M, Erdem Z, Gauglhofer C, Stättner S, Karner J, Klimpfinger M, Wrba F, Reti A, Hegedus B, Baierl A, Grasl-Kraupp B, Holzmann K, Grusch M, Berger W, Marian B.

Cancer Res. 2012 Nov 15;72(22):5767-77. doi: 10.1158/0008-5472.CAN-11-3654. Epub 2012 Sep 12.

37.

The influence of curcumin, quercetin, and eicosapentaenoic acid on the expression of phase II detoxification enzymes in the intestinal cell lines HT-29, Caco-2, HuTu 80, and LT97.

Odenthal J, van Heumen BW, Roelofs HM, te Morsche RH, Marian B, Nagengast FM, Peters WH.

Nutr Cancer. 2012 Aug;64(6):856-63. doi: 10.1080/01635581.2012.700994. Epub 2012 Jul 25.

PMID:
22830632
38.

Taurine chloramine induces apoptosis in human osteosarcoma cell lines.

Pilz M, Holinka J, Vavken P, Marian B, Krepler P.

J Orthop Res. 2012 Dec;30(12):2046-51. doi: 10.1002/jor.22161. Epub 2012 Jun 4.

39.

Celecoxib and tauro-ursodeoxycholic acid co-treatment inhibits cell growth in familial adenomatous polyposis derived LT97 colon adenoma cells.

van Heumen BW, Roelofs HM, Te Morsche RH, Marian B, Nagengast FM, Peters WH.

Exp Cell Res. 2012 Apr 15;318(7):819-27. doi: 10.1016/j.yexcr.2012.02.004. Epub 2012 Feb 14.

PMID:
22366264
40.

The major vault protein mediates resistance to epidermal growth factor receptor inhibition in human hepatoma cells.

Losert A, Lötsch D, Lackner A, Koppensteiner H, Peter-Vörösmarty B, Steiner E, Holzmann K, Grunt T, Schmid K, Marian B, Grasl-Kraupp B, Schulte-Hermann R, Krupitza G, Berger W, Grusch M.

Cancer Lett. 2012 Jun 28;319(2):164-172. doi: 10.1016/j.canlet.2012.01.002. Epub 2012 Jan 17.

PMID:
22261339
41.

Up-regulation of 12(S)-lipoxygenase induces a migratory phenotype in colorectal cancer cells.

Klampfl T, Bogner E, Bednar W, Mager L, Massudom D, Kalny I, Heinzle C, Berger W, Stättner S, Karner J, Klimpfinger M, Fürstenberger G, Krieg P, Marian B.

Exp Cell Res. 2012 Apr 1;318(6):768-78. doi: 10.1016/j.yexcr.2011.12.017. Epub 2011 Dec 29.

42.

Alternative Splicing of Fibroblast Growth Factor Receptor IgIII Loops in Cancer.

Holzmann K, Grunt T, Heinzle C, Sampl S, Steinhoff H, Reichmann N, Kleiter M, Hauck M, Marian B.

J Nucleic Acids. 2012;2012:950508. doi: 10.1155/2012/950508. Epub 2011 Dec 12.

43.

Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition.

Metzner T, Bedeir A, Held G, Peter-Vörösmarty B, Ghassemi S, Heinzle C, Spiegl-Kreinecker S, Marian B, Holzmann K, Grasl-Kraupp B, Pirker C, Micksche M, Berger W, Heffeter P, Grusch M.

J Invest Dermatol. 2011 Oct;131(10):2087-95. doi: 10.1038/jid.2011.177. Epub 2011 Jul 14.

44.

NF-κB mediates the 12(S)-HETE-induced endothelial to mesenchymal transition of lymphendothelial cells during the intravasation of breast carcinoma cells.

Vonach C, Viola K, Giessrigl B, Huttary N, Raab I, Kalt R, Krieger S, Vo TP, Madlener S, Bauer S, Marian B, Hämmerle M, Kretschy N, Teichmann M, Hantusch B, Stary S, Unger C, Seelinger M, Eger A, Mader R, Jäger W, Schmidt W, Grusch M, Dolznig H, Mikulits W, Krupitza G.

Br J Cancer. 2011 Jul 12;105(2):263-71. doi: 10.1038/bjc.2011.194. Epub 2011 May 31.

45.

Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy.

Heinzle C, Sutterlüty H, Grusch M, Grasl-Kraupp B, Berger W, Marian B.

Expert Opin Ther Targets. 2011 Jul;15(7):829-46. doi: 10.1517/14728222.2011.566217. Epub 2011 Mar 7. Review.

PMID:
21375471
46.

Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis.

Gauglhofer C, Sagmeister S, Schrottmaier W, Fischer C, Rodgarkia-Dara C, Mohr T, Stättner S, Bichler C, Kandioler D, Wrba F, Schulte-Hermann R, Holzmann K, Grusch M, Marian B, Berger W, Grasl-Kraupp B.

Hepatology. 2011 Mar;53(3):854-64. doi: 10.1002/hep.24099. Epub 2011 Feb 11.

PMID:
21319186
47.

The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.

Brünner-Kubath C, Shabbir W, Saferding V, Wagner R, Singer CF, Valent P, Berger W, Marian B, Zielinski CC, Grusch M, Grunt TW.

Breast Cancer Res Treat. 2011 Sep;129(2):387-400. doi: 10.1007/s10549-010-1232-1. Epub 2010 Nov 3.

PMID:
21046231
48.

[Tumor stem cell research - basis and challenge for diagnosis and therapy].

Karlic H, Herrmann H, Schulenburg A, Grunt TW, Laffer S, Mirkina I, Hubmann R, Shehata M, Marian B, Selzer E, Pfeilstöcker M, Pittermann E, Jäger U, Pehamberger H, Zielinski C, Valent P.

Wien Klin Wochenschr. 2010 Jul;122(13-14):423-36. doi: 10.1007/s00508-010-1408-z. Epub 2010 Jul 22. Review. German.

PMID:
20645015
49.

Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration.

Sonvilla G, Allerstorfer S, Heinzle C, Stättner S, Karner J, Klimpfinger M, Wrba F, Fischer H, Gauglhofer C, Spiegl-Kreinecker S, Grasl-Kraupp B, Holzmann K, Grusch M, Berger W, Marian B.

Br J Cancer. 2010 Mar 30;102(7):1145-56. doi: 10.1038/sj.bjc.6605596. Epub 2010 Mar 16.

50.

Peroxisome-proliferator-activated receptors γ and β/δ mediate vascular endothelial growth factor production in colorectal tumor cells.

Röhrl C, Kaindl U, Koneczny I, Hudec X, Baron DM, König JS, Marian B.

J Cancer Res Clin Oncol. 2011 Jan;137(1):29-39. doi: 10.1007/s00432-010-0856-1. Epub 2010 Mar 11.

PMID:
20221637

Supplemental Content

Loading ...
Support Center